Friday, 20 October 2017
Latest news
Main » Biogen Inc. (BIIB) Ownership Decreased by Gulf International Bank (uk) Ltd

Biogen Inc. (BIIB) Ownership Decreased by Gulf International Bank (uk) Ltd

12 October 2017

The Kiltearn Partners Llp holds 485,327 shares with $22.72M value, down from 2.74 million last quarter.

Tekla Capital Management Llc increased Biogen Inc. The stock increased 0.11% or $0.36 during the last trading session, reaching $333.19. About shares traded. Biogen Inc (NASDAQ:BIIB) has risen 4.94% since October 10, 2016 and is uptrending.

Based on the latest notes released to investors, 8 analysts have issued a rating of "buy", 10 analysts "outperform", 11 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". As of quarter end Eqis Capital Management, Inc. had acquired 2,556 shares growing its stake by 61.1%. The Tnb Financial holds 23,998 shares with $6.51M value, up from 22,638 last quarter. The company has market cap of $1.57 billion. The stock increased 0.20% or $0.05 during the last trading session, reaching $25.35. It is down 4.94% since October 11, 2016 and is uptrending. It has underperformed by 1.58% the S&P500. On Wednesday, July 26 the stock rating was maintained by H.C. Wainwright with "Buy". Therefore 52% are positive. About 2.14 million shares traded or 21.59% up from the average.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Tuesday, July 25th.

07/10/2017 - Jefferies began new coverage on Biogen Idec Inc. giving the company a "hold" rating. The stock has "Buy" rating by Cowen & Co on Friday, May 26. The rating was initiated by Credit Suisse on Wednesday, January 20 with "Neutral". (NYSE:OIS) on Thursday, August 11 with "Equal-Weight" rating. Zimmer Partners Lp, a New York-based fund reported 992,100 shares.

05/15/2017 - Biogen Idec Inc. had its "overweight" rating reiterated by analysts at Piper Jaffray. (NYSE:GIS) rating on Friday, June 17. The rating was initiated by Gabelli on Friday, October 16 with "Buy". Eads & Heald Invest Counsel reported 1,016 shares. Its down 0.16, from 1.04 in 2017Q1. It improved, as 27 investors sold OIS shares while 47 reduced holdings. 54 funds opened positions while 145 raised stakes. The company has a market capitalization of $70.22 billion, a P/E ratio of 21.79 and a beta of 0.77. (NYSE:GIS) or 9,440 shares. Finally, RMB Capital Management LLC raised its position in Biogen by 1.1% in the first quarter. (NYSE:OIS) for 32,138 shares. Exane Derivatives stated it has 78 shares or 0% of all its holdings. Mark Sheptoff Financial Planning Lc holds 8,960 shares or 0.34% of its portfolio. Motco who had been investing in General Mills Inc for a number of months, seems to be bullish on the $28.93B market cap company. (NYSE:OIS). Parametric Port Associates Lc stated it has 0.01% of its portfolio in Oil States International, Inc. Bessemer Grp reported 60,881 shares. Great West Life Assurance Company Can reported 0.17% stake. Barrow Hanley Mewhinney & Strauss Ltd Llc reported 92,238 shares. Symphony Asset Mngmt Lc accumulated 0.34% or 11,045 shares.

Canadian Pacific Railway Limited (TSE:CP) Files An 8-K Other Events
Arrowstreet Capital Limited Partnership increased its position in Canadian National Railway by 363.0% during the second quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Canadian Pacific Railway Limited by 4.7% during the 2nd quarter.

Motco, which manages about $959.43 million US Long portfolio, decreased its stake in Nestle Sa (NSRGY) by 52,317 shares to 40,701 shares, valued at $3.55 million in 2017Q2, according to the filing. (NYSE:GIS) for 8,146 shares. Amerisourcebergen Corporation (NYSE:ABC) was reduced too. Equities analysts predict that Biogen Inc. will post $21.53 earnings per share for the current fiscal year. L's profit will be $245.74M for 16.65 P/E if the $0.73 EPS becomes a reality. After $5.04 actual EPS reported by Biogen Inc for the previous quarter, Wall Street now forecasts 11.31% EPS growth.

Investors sentiment increased to 1 in 2017 Q2. Its down 0.16, from 1.04 in 2017Q1. The legal version of this piece of content can be read at https://weekherald.com/2017/10/11/ameritas-investment-partners-inc-reduces-holdings-in-biogen-inc-biib.html. Parallax Volatility Advisers Ltd Partnership holds 16,592 shares. Independent Portfolio Consultants Inc. grew its holdings in shares of Biogen by 93.2% in the second quarter. Endurant Capital Mgmt Lp has 2.43% invested in Biogen Inc (NASDAQ:BIIB) for 31,632 shares. Central Savings Bank invested in 0.69% or 9,734 shares.

06/22/2017 - Biogen Idec Inc. had its "market perform" rating reiterated by analysts at Leerink Swann. Channing Management Ltd Limited Liability Company holds 0.28% or 26,657 shares. Sivik Glob Healthcare Ltd Liability holds 1.99% or 20,000 shares. Cornerstone Advsr has invested 0.22% in Biogen Inc (NASDAQ:BIIB). Maple Capital Mngmt reported 869 shares stake. Amica Mutual Insur reported 11,334 shares. Ameriprise Fincl invested in 1.71M shares or 0.23% of the stock. The value of the investment in BIIB increased from $1,135,000 to $2,110,000 a change of $975,000 quarter over quarter. Following the transaction, the executive vice president now directly owns 27,232 shares of the company's stock, valued at approximately $7,761,120.

Since May 1, 2017, it had 1 insider buy, and 1 sale for $102,593 activity. Vounatsos Michel also bought $380,433 worth of Biogen Inc (NASDAQ:BIIB) shares. Posner Brian S sold $277,840 worth of stock.

Biogen, Inc.is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Therefore 58% are positive. Wells Fargo maintained the shares of BIIB in report on Friday, December 4 with "Outperform" rating.

On September 13 BMO Capital kept the company rating at "Market Perform" but moved up the price target from $284.70 to $377.00. The rating was maintained by Wedbush on Tuesday, February 2 with "Neutral". The company was downgraded on Monday, November 14 by Bernstein. The stock has "Buy" rating by Goldman Sachs on Wednesday, July 26. As per Monday, June 12, the company rating was maintained by Jefferies. Vetr raised shares of Biogen from a "buy" rating to a "strong-buy" rating and set a $311.67 price objective for the company in a report on Tuesday, June 27th.